Purpose Veliparib, a poly (ADP ribose) polymerase inhibitor, potentiated standard
chemotherapy against small-cell lung cancer (SCLC) in preclinical studies. We evaluated …

Purpose: This study investigated the efficacy and safety of oral PARP inhibitor veliparib, plus
carboplatin and etoposide in patients with treatment-naïve, extensive-stage small cell lung …

Purpose Considering promising results in phase II studies, a randomized phase III trial was
designed to assess the efficacy of adding bevacizumab to first-line cisplatin plus etoposide …

Purpose To investigate the efficacy and safety of bevacizumab plus cisplatin and etoposide
in patients with extensive-stage disease, small-cell lung cancer (ED-SCLC). Patients and …

Purpose Because of promising efficacy signals in single-arm studies, a placebo-controlled,
double-blind, randomized phase II trial was designed to assess the efficacy and safety of …

Purpose The efficacy of cisplatin, irinotecan, and bevacizumab was evaluated in patients
with extensive-stage small-cell lung cancer (ES-SCLC). Patients and Methods Patients with …

Importance Combinations of chemotherapy with immunotherapy or bevacizumab in first-line
treatments of extensive-stage small cell lung cancer (ES-SCLC) have been evaluated in …

Importance Programmed cell death ligand 1 inhibitors combined with chemotherapy has
changed the approach to first-line treatment in patients with extensive-stage small cell lung …

Introduction Bevacizumab's role in the treatment of small cell lung cancer (SCLC) is
unknown. A multicenter phase II trial with bevacizumab plus chemotherapy was conducted …

Purpose Following a phase II trial in which pemetrexed-platinum demonstrated similar
activity to that of historical etoposide-platinum controls, a phase III study was conducted to …